News ID: 175236
Published: 0928 GMT January 07, 2017

Study reveals genetic driver for rare metaplastic breast cancer

Study reveals genetic driver for rare metaplastic breast cancer

Researchers from the University of Michigan Comprehensive Cancer Center have found a key genetic driver for a rare form of breast cancer.

Dr. Celina Kleer, Harold A. Oberman Collegiate Professor of Pathology and director of the Breast Pathology Program at the University of Michigan Comprehensive Cancer Center, has been studying how the CCN6 protein affects breast cancer development for more than a decade, UPI reported.

Kleer and her team examined the effects of the deletion of CCN6 from the mammary glands in mice.

The results showed delayed development and mammary glands that did not develop properly at different ages in mice.

Kleer said, "After a year, the mice started to form mammary gland tumors.

“These tumors looked identical to human metaplastic breast cancer, with the same characteristics. That was very exciting."

Metaplastic breast cancer is a very rare and aggressive subtype of triple-negative breast cancer. Although 20 percent of all breast cancers are triple-negative, with only one percent being metaplastic.

Kleer added, "Metaplastic breast cancers are challenging to diagnose and treat. In part, the difficulties stem from the lack of mouse models to study this disease."

Metaplastic breast cancer cells are more mesenchymal, a cell state that enables them to move and invade.

Researchers found that deleting CCN6 induced the epithelial process to mesenchymal transition.

Kleer said, "Our hypothesis, based on years of experiments in our lab, was that knocking out this gene would induce breast cancer.

"But we didn't know if knocking out CCN6 would be enough to unleash tumors, and if so, when, or what kind. Now we have a new mouse model, and a new way of studying metaplastic carcinomas, for which there's no other model."

Researchers studied tumors in mice in their new model and were able to identify several potential genes to target with therapeutics.

Security Key:
Captcha refresh
Page Generated in 0/4014 sec